Wangbi
Tablets are widely used in the treatment of
rheumatoid arthritis,
knee osteoarthritis and other diseases at pre-sent. Long-term clinical application and research have shown that this drug has a good effect in reducing the
pain of related diseases and improving symptoms. Due to the lack of guidance in the instructions and currently no relevant norms to guide the clinical application of Wangbi
Tablets, in order to further improve clinicians' understanding of the drug and fully tap the clinical advantages of the drug, the Professional Committee of Orthopedics and Traumatology Drug Research of China Association of Chinese Medicine organized experts in the fields of
rheumatism, orthopedics, pharmacy and methodology in Chinese and western medicine to develop expert consensus on Chinese
patent medicines in accordance with the relevant requirements of the consensus methodology. Based on full consideration of clinical research evidence and expert experience, the clinical issues were summarized in the consensus, and for those clinical problems supported by evidences, the internationally recognized recommendation evaluation and formulation method GRADE was used to evaluate the evidence and form recommendations; for those clinical issues not supported by evidences, a consensus was reached through the nominal group method to form consensus recommendations. The consensus adopted a concise and clear format to form re-commendations or reach consensus suggestions on the medication regimen, medication characteristics, intervention timing, usage and dosage, course of use and safety issues for the treatment of
rheumatoid arthritis and
knee osteoarthritis with Wangbi
Tablets. It is suggested that its application will better improve the efficacy of Wangbi
Tablets in the treatment of
rheumatoid arthritis and
knee osteoarthritis, at the same time provide a reference for clinicians to use Wangbi
Tablets in a standardized, reasonable and safe manner.